



Media Contact:

Nicole Osmer

nicole@nicoleosmer.com

(650) 454-0504

Tryton Announces Events at European Bifurcation Club Meeting

Leading Cardiologists will Discuss Experience with Tryton Stent System

Durham, N.C. – Oct. 13, 2009 – Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced that the company's TRYTON Side Branch Stent™ System will be featured in discussions by a number of leading cardiologists in a symposium on Oct. 16, 2009, in conjunction with the European Bifurcation Club meeting in Berlin, Germany.

Symposium presenters who will discuss the Tryton solution include Antonio Bartorelli, M.D., director of Interventional Cardiology, CCM, and Professor of Cardiology, University of Milan; Maciej Lesiak M.D., Ph.D. Department of Cardiology, University Hospital in Poznan; and Patrick W. Serruys, M.D., Ph.D., of Erasmus Medical Center in Rotterdam, the Netherlands.

"This is an exciting time for Tryton. Hundreds of patients with difficult-to-treat cases have now been helped by physicians utilizing our device, and our solution for bifurcation lesions is gaining the attention of some of the world's most renowned cardiologists," said J. Greg Davis, president and CEO of Tryton Medical. "We look forward to participating in the annual European Bifurcation Club meeting this week, which serves as an ideal forum for clinicians to share best practices for treating bifurcation lesions."

Tryton Medical at the European Bifurcation Club Meeting 2009

Also on Oct. 16, Dr. Bartorelli will present during the European Bifurcation Club meeting his experience using the Tryton stent system. As part of that presentation he will provide an update on results of a study analyzing acute and long-term results of the Tryton Side Branch Stent used in conjunction with Abbott's XIENCE V® Everolimus Eluting Coronary Stent System.

About the Tryton Side Branch Stent System

The Tryton Side Branch Stent System is designed to offer a dedicated strategy for treating atherosclerotic lesions in the side branch at the site of a bifurcation. These areas of the vascular system are a common location for plaque and are particularly challenging to treat with currently available stent systems. Approximately twenty percent of patients treated for coronary artery disease have diseased bifurcated lesions.

TRYTON MEDICAL, INC.

1000 Park Forty Plaza, Suite 325

Durham, NC 27713

PHONE 919 / 226.1490

FAX 919 / 226.1497

info@trytonmedical.com

Tryton's highly deliverable cobalt chromium stent is deployed in the side branch artery using a standard single-wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel.

The Tryton Side Branch Stent System demonstrated excellent six-month clinical results in a first-in-man study of the system in 30 patients, with no restenosis occurring in the side branch artery. The stent system has received CE Mark approval in Europe and is not approved in the United States.

About Tryton Medical, Inc.

Tryton Medical, Inc., located in Durham, N.C., is a leading developer of novel stent systems for the treatment of bifurcation lesions. The company's Side Branch Stent System, approved for sale in Europe, is designed to offer a dedicated strategy for treating these challenging cases. The privately held company is backed by Spray Ventures, PTV Sciences, and RiverVest Ventures. For more information please visit www.trytonmedical.com.

###